Cytoki Pharma

Cytoki Pharma is a biotechnology company focused on serious diseases caused by epithelial injury with unmet medical need. The company was founded in 2019 after licensing of full pharma program from Novo Nordisk with seed financing from Lundbeckfonden Emerge, followed by a $45 M series A from a syndicate of strong international investors. Cytoki is run by a team of experienced pharma executives with deep expertise in IL-22 biology, lipidation technology and drug development. Our long-acting lipidated IL-22 analogue program with promise as treatment for diseases involving epithelial injury – particularly IBD – is on track for Phase 1 start in late 2022.

Contact name:

Rasmus Jørgensen


Tuborg Boulevard 12, DK-2900 Hellerup



Number of employees:


If you cannot find what you are looking for or if you have feedback to our website, please do not hesitate to contact or +45 7172 1114

Copyright 2022 DANISH BIO – DANSK BIOTEK. All rights reserved.